We are analyzing https://link.springer.com/article/10.1007/bf02267084.

Title:
A polymorphism but no mutations in the GADD45 gene in breast cancers | Human Genetics
Description:
The p53 gene product is part of a pathway regulating growth arrest at the G1 checkpoint of the cell cycle. Mutation of other components of this pathway, including the products of the ataxia telangiectasia (AT), GADD45, mdm2, and p21WAF1/CIP1 genes may have effects comparable to mutations in the p53 gene. The GADD45 gene is induced by ionizing radiation and several DNA-damaging xenobiotics. Induction requires the binding of wild-type p53 to an evoulutionarily highly conserved putative intronic p53 binding site in intron 3 of GADD45. We recently analyzed the entire coding region of the p53 gene in primary breast cancers of Midwestern white women and found 21 mutations among 53 tumors (39,6%). We now have shown by direct sequencing that there are no mutations in the intronic p53 binding site of the GADD45 gene in any of the 53 primary breast cancers and no mutations in the entire coding region of the GADD45 gene in a subset of 26 consecutive tumors (12 with p53 mutation and 14 without p53 mutation). The only sequence variation detected was a common polymorphism in intron 3. The absence of mutations in the GADD45 gene, including the putative p53-binding intronic site, suggests that this gene is not a frequent target of mutations in breast cancer. Although mutations of the p53 gene have been studied in a wide spectrum of human cancers, GADD45 has not been examined in any tumor or cell line to the best of our knowledge. Our results raise the possibility that mutation of the GADD45 gene alone is not functionally equivalent to loss of wild-type p53 activity.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

google, scholar, cancer, gene, mutations, gadd, breast, human, cell, article, cancers, mdm, res, mutation, sommer, arrest, protein, oncogene, privacy, cookies, site, genetics, blaszyk, hartmann, growth, genes, binding, sequencing, zhan, natl, content, analysis, publish, search, polymorphism, pathway, checkpoint, cycle, dnadamaging, induction, tumor, access, ataxiatelangiectasia, mammalian, eldeiry, agents, biol, suppressor, amplification, inst,

Topics {✒️}

p53-dependent gamma-ray response month download article/chapter phage promoter-based methods inhibits p53-mediated transactivation wild-type p53 activity primary breast cancers p53-regulated protein gadd45 sequence variation detected growth arrest signals growth-arrest genes midwestern white women fornace aj jr el-deiry ws consensus binding site privacy choices/manage cookies fornance aj jr direct sequencing wild-type p53 tumour suppressor p53 full article pdf growth arrest human bladder cancer p53 gene product mammalian gadd45 gene cellular p53 activity cultured human cells wtp53 human cells human malignant gliomas european economic area scope submit manuscript g1 checkpoint p21waf1/cip1 genes dna-damaging xenobiotics entire coding region o'conner pm genotoxicstress-response genes epithelial solid neoplasia de vries emg e6 oncoprotein encoded polymerase chain reaction friedrich-schiller-university p53 gene mutation dna-damaging agents dna damaging agents conditions privacy policy midwestern united states waf1-cip1 gene check access instant access missense-type mutations

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A polymorphism but no mutations in the GADD45 gene in breast cancers
         description:The p53 gene product is part of a pathway regulating growth arrest at the G1 checkpoint of the cell cycle. Mutation of other components of this pathway, including the products of the ataxia telangiectasia (AT), GADD45, mdm2, and p21WAF1/CIP1 genes may have effects comparable to mutations in the p53 gene. The GADD45 gene is induced by ionizing radiation and several DNA-damaging xenobiotics. Induction requires the binding of wild-type p53 to an evoulutionarily highly conserved putative intronic p53 binding site in intron 3 of GADD45. We recently analyzed the entire coding region of the p53 gene in primary breast cancers of Midwestern white women and found 21 mutations among 53 tumors (39,6%). We now have shown by direct sequencing that there are no mutations in the intronic p53 binding site of the GADD45 gene in any of the 53 primary breast cancers and no mutations in the entire coding region of the GADD45 gene in a subset of 26 consecutive tumors (12 with p53 mutation and 14 without p53 mutation). The only sequence variation detected was a common polymorphism in intron 3. The absence of mutations in the GADD45 gene, including the putative p53-binding intronic site, suggests that this gene is not a frequent target of mutations in breast cancer. Although mutations of the p53 gene have been studied in a wide spectrum of human cancers, GADD45 has not been examined in any tumor or cell line to the best of our knowledge. Our results raise the possibility that mutation of the GADD45 gene alone is not functionally equivalent to loss of wild-type p53 activity.
         datePublished:
         dateModified:
         pageStart:543
         pageEnd:547
         sameAs:https://doi.org/10.1007/BF02267084
         keywords:
            Breast Cancer
            White Woman
            Direct Sequencing
            Growth Arrest
            Primary Breast Cancer
            Human Genetics
            Molecular Medicine
            Gene Function
            Metabolic Diseases
         image:
         isPartOf:
            name:Human Genetics
            issn:
               1432-1203
               0340-6717
            volumeNumber:97
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:H. Blaszyk
               affiliation:
                     name:Mayo Clinic and Mayo Foundation
                     address:
                        name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Hartmann
               affiliation:
                     name:Mayo Clinic and Mayo Foundation
                     address:
                        name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. S. Sommer
               affiliation:
                     name:Mayo Clinic and Mayo Foundation
                     address:
                        name:Department of Biochemistry and Molecular Biology, Mayo Clinic and Mayo Foundation, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. S. Kovach
               affiliation:
                     name:Mayo Clinic and Mayo Foundation
                     address:
                        name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A polymorphism but no mutations in the GADD45 gene in breast cancers
      description:The p53 gene product is part of a pathway regulating growth arrest at the G1 checkpoint of the cell cycle. Mutation of other components of this pathway, including the products of the ataxia telangiectasia (AT), GADD45, mdm2, and p21WAF1/CIP1 genes may have effects comparable to mutations in the p53 gene. The GADD45 gene is induced by ionizing radiation and several DNA-damaging xenobiotics. Induction requires the binding of wild-type p53 to an evoulutionarily highly conserved putative intronic p53 binding site in intron 3 of GADD45. We recently analyzed the entire coding region of the p53 gene in primary breast cancers of Midwestern white women and found 21 mutations among 53 tumors (39,6%). We now have shown by direct sequencing that there are no mutations in the intronic p53 binding site of the GADD45 gene in any of the 53 primary breast cancers and no mutations in the entire coding region of the GADD45 gene in a subset of 26 consecutive tumors (12 with p53 mutation and 14 without p53 mutation). The only sequence variation detected was a common polymorphism in intron 3. The absence of mutations in the GADD45 gene, including the putative p53-binding intronic site, suggests that this gene is not a frequent target of mutations in breast cancer. Although mutations of the p53 gene have been studied in a wide spectrum of human cancers, GADD45 has not been examined in any tumor or cell line to the best of our knowledge. Our results raise the possibility that mutation of the GADD45 gene alone is not functionally equivalent to loss of wild-type p53 activity.
      datePublished:
      dateModified:
      pageStart:543
      pageEnd:547
      sameAs:https://doi.org/10.1007/BF02267084
      keywords:
         Breast Cancer
         White Woman
         Direct Sequencing
         Growth Arrest
         Primary Breast Cancer
         Human Genetics
         Molecular Medicine
         Gene Function
         Metabolic Diseases
      image:
      isPartOf:
         name:Human Genetics
         issn:
            1432-1203
            0340-6717
         volumeNumber:97
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:H. Blaszyk
            affiliation:
                  name:Mayo Clinic and Mayo Foundation
                  address:
                     name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Hartmann
            affiliation:
                  name:Mayo Clinic and Mayo Foundation
                  address:
                     name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. S. Sommer
            affiliation:
                  name:Mayo Clinic and Mayo Foundation
                  address:
                     name:Department of Biochemistry and Molecular Biology, Mayo Clinic and Mayo Foundation, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. S. Kovach
            affiliation:
                  name:Mayo Clinic and Mayo Foundation
                  address:
                     name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Human Genetics
      issn:
         1432-1203
         0340-6717
      volumeNumber:97
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic and Mayo Foundation
      address:
         name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
         type:PostalAddress
      name:Mayo Clinic and Mayo Foundation
      address:
         name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
         type:PostalAddress
      name:Mayo Clinic and Mayo Foundation
      address:
         name:Department of Biochemistry and Molecular Biology, Mayo Clinic and Mayo Foundation, Rochester, USA
         type:PostalAddress
      name:Mayo Clinic and Mayo Foundation
      address:
         name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:H. Blaszyk
      affiliation:
            name:Mayo Clinic and Mayo Foundation
            address:
               name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
               type:PostalAddress
            type:Organization
      name:A. Hartmann
      affiliation:
            name:Mayo Clinic and Mayo Foundation
            address:
               name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
               type:PostalAddress
            type:Organization
      name:S. S. Sommer
      affiliation:
            name:Mayo Clinic and Mayo Foundation
            address:
               name:Department of Biochemistry and Molecular Biology, Mayo Clinic and Mayo Foundation, Rochester, USA
               type:PostalAddress
            type:Organization
      name:J. S. Kovach
      affiliation:
            name:Mayo Clinic and Mayo Foundation
            address:
               name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
      name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
      name:Department of Biochemistry and Molecular Biology, Mayo Clinic and Mayo Foundation, Rochester, USA
      name:Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(71)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.64s.

LINK . SPRINGER . COM {}